Quarterly ResultNov 6, 2026, 06:08 AM
Starling Oncology Q3 Revenue Up 24.3% to $169.8M; Net Loss Narrows
AI Summary
Starling Oncology, Inc. (formerly The Oncology Institute, Inc.) reported its third-quarter financial results for 2026. Total operating revenue saw a significant increase of 24.3% year-over-year, reaching $169.8 million, primarily driven by a 44.1% surge in Specialty Pharmacy revenue to $109.3 million. Despite the revenue growth, the company reported a net loss of $15.7 million for the quarter, a slight improvement from $16.5 million in the prior year's quarter. The net loss per diluted share was $0.13, down from $0.14 in Q3 2025. Total assets grew to $187.8 million, while total liabilities increased to $225.1 million. Cash and cash equivalents stood at $36.9 million.
Key Highlights
- Total operating revenue increased to $169.8M in Q3 2026 from $136.6M in Q3 2025, a 24.3% YoY increase.
- Specialty Pharmacy revenue surged to $109.3M in Q3 2026 from $75.9M in Q3 2025, a 44.1% YoY increase.
- Net loss for Q3 2026 was $15.7M, compared to $16.5M in Q3 2025.
- Net loss per share (diluted) was $0.13 in Q3 2026, compared to $0.14 in Q3 2025.
- Total assets grew to $187.8M as of September 30, 2026, from $164.7M as of December 31, 2025.
- Total liabilities increased to $225.1M as of September 30, 2026, from $180.4M as of December 31, 2025.
- Cash and cash equivalents increased to $36.9M as of September 30, 2026, from $33.6M as of December 31, 2025.
Price Impact
More from TOI